Announcement PDF Rule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public. Introduced 30/09/01 Amended 01/01/11 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Part 1 - Change of director's relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part. Part 2 - Change of director's relevant interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part. Appendix 3Y Change of Director's Interest Notice Name of entity Resonance Health Limited ABN 96 006 762 492 Name of director David Fuller Date of last notice 28 April 2026 Direct or indirect interest Indirect - D1 UK SMSF Pty Ltd <D1 UK SMSF A/C> Nature of indirect interest (including registered holder) D1 UK SMSF Pty Ltd <D1 UK SMSF A/C>, is an entity controlled by David Fuller Date of change 22 May 2026 No. of securities held prior to change Nil Class ORDINARY FULLY PAID SHARES Number acquired 98,701 Number disposed NIL Value/Consideration $3,962.99 ($0.04 per share) No. of securities held after change 98,701 Nature of change On market purchase Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which interest related prior to change N/A + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Part 3 - +Closed period Appendix 3Y Change of Director's Interest Notice Interest acquired N/A Interest disposed N/A Value/Consideration N/A Interest after change N/A Were the interests in the securities or contracts detailed above traded during a + closed period where prior written clearance was required? No If so, was prior written clearance provided to allow the trade to proceed during this period? N/A If prior written clearance was provided, on what date was this provided? N/A + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 2